Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

UK's Vectura bows to sweetened 1.1 billion stg Philip Morris offer

Published 08/12/2021, 12:30 PM
Updated 08/12/2021, 01:46 PM
© Reuters. FILE PHOTO: A Philip Morris logo is pictured on a factory in Serrieres near Neuchatel, Switzerland December 8, 2017/File Photo
PM
-

By Yadarisa Shabong

(Reuters) -Cigarette maker Philip Morris won the support of Vectura for its 1.1 billion pound ($1.5 billion) takeover offer for the inhaled treatments maker after outbidding private equity firm Carlyle, the British company said on Thursday.

Philip Morris International (NYSE:PM) (PMI) on Sunday sweetened its offer for the asthma drugmaker to 165 pence per share, surpassing Carlyle's final 155p proposal.

Vectura said it considered the terms of the Philip Morris offer to be fair and reasonable and its board planned to unanimously recommend the bid to shareholders.

Vectura's backing for the Philip Morris deal comes despite the company previously noting the uncertainties that could arise as a result of it being owned by the Marlboro cigarette maker.

Philip Morris aims to use Vectura's expertise with inhalable formulations and device design to produce a range of over-the-counter and prescription-based respiratory therapies.

Its interest also comes at a time when big tobacco has been trying to change its image following years of negative press and lawsuits for selling health-harming cigarettes.

PMI, which on Tuesday switched its proposal to a takeover offer from a so-called scheme of arrangement to up its chances, needs the acceptances of holders of just over 50% of Vectura shares for the deal to go through.

There will be no shareholder meeting. Instead, the offer will be open for a minimum of 21 days, unless extended, and PMI needs to satisfy the acceptance condition in the next 60 days.

Carlyle had said last week Vectura shareholders AXA Investment Managers, TIG Advisors and Berry Street Capital indicated their support for the buyout firm's deal. They together hold a stake of about 11.2% in the drugmaker.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The bidding war between the two American suitors drew the intervention of Britain's takeover regulator on Monday to break the impasse.

London-listed shares of Vectura closed at 163.2 pence on Thursday. They have gained 33% since the first takeover proposal in May. 

($1 = 0.7234 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.